A dynamic model for assessing universal Hepatitis A vaccination in Canada

C. T. Bauch; Arni S R Rao; B. Z. Pham; M. Krahn; V. Gilca; B. Duval; M. H. Chen; A. C. Tricco

doi:10.1016/j.vaccine.2006.11.020

A dynamic model for assessing universal Hepatitis A vaccination in Canada

C. T. Bauch, Arni S R Rao, B. Z. Pham, M. Krahn, V. Gilca, B. Duval, M. H. Chen, A. C. Tricco

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Vaccination against Hepatitis A virus (HAV) in Canada is currently targeted toward high-risk groups. However, universal vaccination has been adopted in several other countries with a similar disease burden. Here we develop an age-structured compartmental model of HAV transmission and vaccination in Canada to assess potential universal vaccination strategies. The model predicts that universal vaccination at age 1 (respectively 4, 9, 15), with phasing out of targeted vaccination, would reduce reported incidence by 60% (respectively 52, 36, 31%) and mortality attributable to HAV by 56% (respectively 45, 26, 25%), relative to continued targeted vaccination, over 80 years.

Original language	English (US)
Pages (from-to)	1719-1726
Number of pages	8
Journal	Vaccine
Volume	25
Issue number	10
DOIs	https://doi.org/10.1016/j.vaccine.2006.11.020
State	Published - Feb 26 2007
Externally published	Yes

Keywords

Hepatitis A
Transmission model
Universal vaccination

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2006.11.020

Cite this

@article{596df4e28a844f64952ef102c0306577,

title = "A dynamic model for assessing universal Hepatitis A vaccination in Canada",

abstract = "Vaccination against Hepatitis A virus (HAV) in Canada is currently targeted toward high-risk groups. However, universal vaccination has been adopted in several other countries with a similar disease burden. Here we develop an age-structured compartmental model of HAV transmission and vaccination in Canada to assess potential universal vaccination strategies. The model predicts that universal vaccination at age 1 (respectively 4, 9, 15), with phasing out of targeted vaccination, would reduce reported incidence by 60% (respectively 52, 36, 31%) and mortality attributable to HAV by 56% (respectively 45, 26, 25%), relative to continued targeted vaccination, over 80 years.",

keywords = "Hepatitis A, Transmission model, Universal vaccination",

author = "Bauch, {C. T.} and Rao, {Arni S R} and Pham, {B. Z.} and M. Krahn and V. Gilca and B. Duval and Chen, {M. H.} and Tricco, {A. C.}",

note = "Funding Information: This work was supported by a Canadian Institutes of Health Research Industry-Partnered Grant in conjunction with GlaxoSmithKline. ",

year = "2007",

month = feb,

day = "26",

doi = "10.1016/j.vaccine.2006.11.020",

language = "English (US)",

volume = "25",

pages = "1719--1726",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "10",

}

TY - JOUR

T1 - A dynamic model for assessing universal Hepatitis A vaccination in Canada

AU - Bauch, C. T.

AU - Rao, Arni S R

AU - Pham, B. Z.

AU - Krahn, M.

AU - Gilca, V.

AU - Duval, B.

AU - Chen, M. H.

AU - Tricco, A. C.

N1 - Funding Information: This work was supported by a Canadian Institutes of Health Research Industry-Partnered Grant in conjunction with GlaxoSmithKline.

PY - 2007/2/26

Y1 - 2007/2/26

N2 - Vaccination against Hepatitis A virus (HAV) in Canada is currently targeted toward high-risk groups. However, universal vaccination has been adopted in several other countries with a similar disease burden. Here we develop an age-structured compartmental model of HAV transmission and vaccination in Canada to assess potential universal vaccination strategies. The model predicts that universal vaccination at age 1 (respectively 4, 9, 15), with phasing out of targeted vaccination, would reduce reported incidence by 60% (respectively 52, 36, 31%) and mortality attributable to HAV by 56% (respectively 45, 26, 25%), relative to continued targeted vaccination, over 80 years.

AB - Vaccination against Hepatitis A virus (HAV) in Canada is currently targeted toward high-risk groups. However, universal vaccination has been adopted in several other countries with a similar disease burden. Here we develop an age-structured compartmental model of HAV transmission and vaccination in Canada to assess potential universal vaccination strategies. The model predicts that universal vaccination at age 1 (respectively 4, 9, 15), with phasing out of targeted vaccination, would reduce reported incidence by 60% (respectively 52, 36, 31%) and mortality attributable to HAV by 56% (respectively 45, 26, 25%), relative to continued targeted vaccination, over 80 years.

KW - Hepatitis A

KW - Transmission model

KW - Universal vaccination

UR - http://www.scopus.com/inward/record.url?scp=33846691934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846691934&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.11.020

DO - 10.1016/j.vaccine.2006.11.020

M3 - Article

C2 - 17229493

AN - SCOPUS:33846691934

SN - 0264-410X

VL - 25

SP - 1719

EP - 1726

JO - Vaccine

JF - Vaccine

IS - 10

ER -

A dynamic model for assessing universal Hepatitis A vaccination in Canada

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this